Remdesivir: Antiviral Drug Explained | MolForge

What is Remdesivir?

Remdesivir, marketed under the brand name Veklury, is a potent antiviral medication developed by Gilead Sciences. It belongs to a class of drugs known as nucleotide analog antivirals. Initially investigated for its potential against other RNA viruses like Hepatitis C and Respiratory Syncytial Virus (RSV), Remdesivir gained significant global attention for its role in treating severe cases of Coronavirus Disease 2019 (COVID-19), caused by the SARS-CoV-2 virus. As a prodrug, Remdesivir is metabolized in the body to its active form, which then interferes with viral RNA replication. Its development and deployment marked a crucial step in the therapeutic armamentarium against emerging viral threats.

Mechanism of Action

The antiviral efficacy of Remdesivir stems from its ability to act as a molecular mimic of adenosine, one of the essential building blocks of RNA. Once administered, Remdesivir is intracellularly converted into its active triphosphate metabolite, adenosine triphosphate analog (remdesivir triphosphate, RDV-TP). This active form then competes with endogenous adenosine triphosphate (ATP) for incorporation into nascent viral RNA strands by viral RNA-dependent RNA polymerase (RdRp).

Upon successful incorporation into the growing RNA chain, Remdesivir causes delayed chain termination. Unlike some other nucleoside analogs that cause immediate chain termination, Remdesivir's structure allows for the addition of a few more nucleotides before stalling the polymerase. This delayed termination effectively hinders viral RNA replication, a critical process for the propagation of many RNA viruses. By disrupting this fundamental viral machinery, Remdesivir limits the production of new virus particles, thereby aiding the host's immune system in controlling the infection.

The specific target enzyme for SARS-CoV-2 is its RdRp, which is essential for replicating the viral genome. Remdesivir's structural similarity to adenosine allows it to be recognized and utilized by the viral polymerase. However, its unique chemical structure prevents the enzyme from proceeding with further elongation of the RNA strand after its incorporation, effectively halting viral replication.

Clinical Uses & Indications

Remdesivir (Veklury) has received emergency use authorization and full FDA approval for specific indications related to viral infections. Its most prominent use has been in the treatment of COVID-19.

FDA-Approved Indications for Remdesivir:

• Hospitalized adults and pediatric patients (12 years of age and older weighing at least 40 kg) requiring supplemental oxygen (low- or high-flow oxygen, or mechanical ventilation or ECMO): Remdesivir is indicated for the treatment of COVID-19. It is typically administered intravenously in a hospital setting. The goal is to reduce the duration of illness and viral shedding in patients with moderate to severe disease.

While initially explored for other viral infections, its primary approved and widely recognized application remains within the context of COVID-19 management. It is crucial to note that Remdesivir is most effective when administered early in the course of the disease, before the virus has caused extensive damage to the lungs and other organs. Its use is generally recommended for patients who are hospitalized and meet specific criteria for disease severity and oxygen requirements.

Dosage & Administration

Remdesivir is administered intravenously, typically in a hospital or clinical setting capable of monitoring patients for adverse reactions. The standard dosage and administration regimen are as follows:

Standard Dosing for COVID-19:

• Initial Dose: A single loading dose of 200 mg administered as an intravenous infusion over 30 to 60 minutes on Day 1.
• Subsequent Doses: For the following days (Day 2 onwards), a dose of 100 mg is administered as an intravenous infusion over 30 to 60 minutes once daily.
• Duration of Treatment: The recommended duration of treatment is typically 5 days. In some cases, particularly for patients requiring invasive mechanical ventilation or ECMO, treatment may be extended up to 10 days.

It is essential that the healthcare provider determines the appropriate dosage and duration based on the patient's clinical status, response to treatment, and specific circumstances. The infusion must be administered by a qualified healthcare professional, and patients should be closely monitored during and after administration for any signs of hypersensitivity or adverse reactions.

Side Effects & Safety

Like all medications, Remdesivir can cause side effects, ranging from mild to severe. Patients receiving Remdesivir should be monitored closely by healthcare professionals.

Common Side Effects:

• Nausea
• Elevated liver enzymes (transaminases), which may indicate liver inflammation or injury. Regular monitoring of liver function tests is recommended.
• Bradycardia (slow heart rate)
• Hypersensitivity reactions (allergic reactions)

Serious Side Effects:

• Hypersensitivity Reactions: Severe infusion-related reactions, including hypotension, hypertension, bradycardia, tachycardia, angioedema, rash, pruritus, sweating, and nausea, have been reported. These reactions can occur during or after the infusion.
• Hepatotoxicity: Increases in serum ALT, AST, and bilirubin have been observed. Close monitoring of liver function tests is crucial. If significant liver enzyme elevations occur, treatment may need to be interrupted or discontinued.
• Renal Impairment: While not a direct contraindication, caution is advised in patients with severe renal impairment.

Contraindications:

Remdesivir is generally contraindicated in patients with a known hypersensitivity to the active substance or any of the excipients. Specific contraindications related to co-administered medications may also apply.

Healthcare providers must weigh the potential benefits of Remdesivir against the risks of side effects for each patient. Patients should report any new or worsening symptoms to their healthcare provider immediately.

Drug Interactions

The potential for drug interactions with Remdesivir is an important consideration in its clinical use. While Remdesivir itself is not extensively metabolized by common cytochrome P450 (CYP) enzymes, its active metabolite and potential effects on drug transporters warrant attention.

Notable Interactions:

• Chloroquine and Hydroxychloroquine: The concomitant use of Remdesivir with chloroquine or hydroxychloroquine is not recommended. These drugs may antagonize the in vitro antiviral activity of Remdesivir, potentially reducing its efficacy.
• Other Antivirals: Interactions with other antiviral agents should be evaluated on a case-by-case basis, considering their mechanisms of action and metabolic pathways.
• Drugs Affecting Hepatic Function: Since elevated liver enzymes have been observed with Remdesivir, caution should be exercised when co-administering with other drugs known to affect liver function.

It is imperative for healthcare providers to review a patient's complete medication list, including over-the-counter drugs and herbal supplements, before initiating Remdesivir therapy. Patients should also inform their doctors about any new medications they start during treatment.

Molecular Properties

Understanding the molecular properties of Remdesivir is key to comprehending its behavior as a drug and its interactions within biological systems.

Key Molecular Information:

• Molecular Formula: C₂₇H₃₅N₆O₈P
• Molecular Weight: Approximately 602.57 g/mol
• Structure Description: Remdesivir is a complex molecule characterized as a 1'-cyano-substituted 2'-methyl-4'- (or 5'-) substituted adenosine nucleoside analog. It features a phosphoramidate prodrug moiety that facilitates its cellular uptake and intracellular conversion to the active triphosphate form. The structure includes a viral polymerase inhibitor component designed to mimic natural nucleosides.
• SMILES Notation: CCC(CC)COC(=O)[C@H](C)NP(=O)(OC1CCCC1)Oc1ccc(c2nc3c(N)ncnn3n2)[C@H](O)[C@@H]1O

The SMILES (Simplified Molecular Input Line Entry System) string, CCC(CC)COC(=O)[C@H](C)NP(=O)(OC1CCCC1)Oc1ccc(c2nc3c(N)ncnn3n2)[C@H](O)[C@@H]1O, provides a linear representation of Remdesivir's chemical structure. This notation is crucial for computational analysis, database searching, and understanding the molecule's connectivity and stereochemistry. The complex structure, including its chiral centers and the phosphoramidate group, is integral to its function as a prodrug and its ability to interfere with viral RNA synthesis.

Analyze Remdesivir with MolForge

The detailed exploration of molecules like Remdesivir, from their intricate structures to their complex mechanisms of action and clinical applications, highlights the power of advanced computational tools in pharmaceutical research. Understanding the nuances of antiviral drugs, their interactions, and their molecular properties is fundamental to drug discovery and development.

At MolForge, we leverage cutting-edge AI to empower researchers and scientists. Our platform provides sophisticated tools to analyze molecular properties, predict drug interactions, explore structure-activity relationships, and accelerate the discovery of novel therapeutics. We invite you to experience the future of molecular discovery. Analyze Remdesivir and countless other molecules with unparalleled precision and speed. Visit our dashboard to begin your exploration today.